The Mollie Study, a Study to Evaluate the Safety and Efficacy of the Mollie Medical Device
DAT: Dyspareunia Alleviation Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Leigh Ann Grossman
- Phone Number: 217-615-1144
- Email: leighann176@yahoo.com
Study Locations
-
-
Illinois
-
Decatur, Illinois, United States, 62526
- Recruiting
- Vero Clinics
-
Contact:
- Leigh Ann Grossman
- Phone Number: 217-615-1144
- Email: leighann176@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: Females 18 years of age and older with a diagnosis of collision dyspareunia -
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treatment
Actual treatment device
|
medical device
Other Names:
|
|
Sham Comparator: Sham
Sham/placebo device
|
medical device
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dyspareunia Alleviation
Time Frame: 12 weeks
|
The Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v.4.0,
Change from Baseline in Pain Scores on the Visual Analog Scale at 13 Weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CIP-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyspareunia
-
NCT05844189Completed
-
NCT04201041Completed
-
NCT01319968CompletedVulvovaginal Atrophy | Dyspareunia Among Puerperal Women
-
NCT07658703Active, not recruiting
-
NCT06730776Not yet recruitingDyspareunia (Female)
-
NCT03647189CompletedVaginal Atrophy, Sexual Dysfunction, Vaginal Dryness, Dyspareunia
-
NCT06142851Not yet recruitingSuperficial Dyspareunia
-
NCT05806203Recruiting
Clinical Trials on Mollie device
-
NCT07485582Not yet recruitingObstructive Sleep Apnea
-
NCT01914302Completed
-
NCT03716947UnknownDegenerative Disc Disease | Discogenic Low Back Pain
-
NCT05653583Not yet recruitingAtrial Fibrillation
-
NCT02326337Completed
-
NCT02940106Terminated
-
NCT05933616CompletedGlucose Metabolism Disorders | Diabetes Mellitus | Endocrine System Diseases | Metabolic Disease
-
NCT07548320CompletedTinnitus | Subjective Tinnitus
-
NCT05033600CompletedUnspecified Trauma- and Stressor-Related Disorder